Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of new clean-surface nanotechnology (CSN) therapies. The company is headquartered in Salt Lake City, Utah.
| Revenue (TTM) | 134,000 |
| Gross Profit (TTM) | 111,000 |
| EBITDA | $-19.62M |
| Operating Margin | -13740.00% |
| Return on Equity | -1738.00% |
| Return on Assets | -56.10% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $-1.60 |
| Price-to-Book | 7.83 |
| Price-to-Sales (TTM) | 583.61 |
| EV/Revenue | 707.64 |
| EV/EBITDA | -1.13 |
| Quarterly Earnings Growth (YoY) | 61.40% |
| Quarterly Revenue Growth (YoY) | -81.50% |
| Shares Outstanding | $12.78M |
| Float | $10.50M |
| % Insiders | 17.06% |
| % Institutions | 20.44% |
Volatility is currently contracting
Clene (CLNN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Clene Inc. (CLNN) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.5 per share a year ago.
After successful completion of FDA Type C meeting, Clene expects to submit an NDA for CNM-Au8 ® under the accelerated approval pathway in the third quarter of 2026 In January 2026, Clene completed an o versubscribed registered direct offering totaling over $28 million, including an initial tranche of more than $6 million and two additional tranches totaling over $22 million tied to regulatory milestones In May 2026, Clene amended its existing $10 million convertible debt facility, extending maturity by six months to August 2027 and eliminating required monthly principal and interest payments before maturity In May 2026, Clene completed a $7 million underwritten registered direct offering with a single investor SALT LAKE CITY, May 14, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late-stage clinical biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its first quarter 2026 financial results and provided recent updates on its CNM-Au8 programs. “We were encouraged by the constructive dialogue during our recent Type C meeting with the FDA and appreciate the Agency's engagement as we advance toward a planned NDA submission for CNM-Au8 under the accelerated approval pathway for patients with ALS,” said Rob Etherington, President and CEO of Clene.
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary, Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced the pricing of an underwritten registered direct offering of 1,000,000 shares of common stock at a purchase price of $7.00 per share to a single investor.
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will participate in the following investor conferences in May. Emerging Growth Conference Date: May 6, 2026 Time of Presentation: 3:25 p.m.
FDA stated that the “proposed data may be capable of supporting the submission and review of an [NDA] under the accelerated approval pathway” for CNM-Au8 based on neurofilament light (NfL) biomarker data FDA acknowledged NfL could potentially serve as a reasonably likely surrogate endpoint Clene expects to submit an NDA for CNM-Au8 to the FDA in the third quarter of 2026 CNM-Au8 represents a potential first-in-class therapeutic approach for ALS, a disease area with significant unmet medical need SALT LAKE CITY, May 04, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced receipt of final meeting minutes following its recent Type C meeting with the U.S. Food and Drug Administration (FDA). During the meeting and confirmed in the final meeting minutes, the FDA stated that Clene's “proposed data may be capable of supporting the submission and review of an [New Drug Application (NDA)] under the accelerated approval pathway for the treatment of ALS.
